Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2011;1(1):14-19.

The role of glypican-3 in regulating Wnt in hepatocellular carcinomas

Wei Gao, Mitchell Ho

The role of glypican-3 in regulating Wnt in hepatocellular carcinomas

Wei Gao et al. Cancer Rep. 2011.

Abstract

Glypican-3 (GPC3) is highly expressed in human hepatocellular carcinoma (HCC) and a growing body of evidence supports the role of GPC3 in HCC pathogenesis. In this review, we discuss recent developments regarding the regulation of GPC3 in HCC and provide insight about GPC3 as a potential therapeutic target in liver cancer. One of the most well studied pathways related to the biological functions of GPC3 is the Wnt signaling pathway. GPC3 may form a complex with Wnt and stimulates HCC growth. GPC3 does this by facilitating and/or stabilizing the interaction between Wnt and Frizzled, leading to the activation of downstream signaling pathways. This signaling complex is also affected by Sulfatase 2 (SULF2), a heparin-degrading endosulfatase. Removing the sulfate groups from GPC3 enhances Wnt signaling and HCC proliferation suggesting that GPC3, Wnts and SULF2 may be part of "a glypican-Wnt/growth factor complex", which may determine cell growth, differentiation and migration. Given the high expression of GPC3 in HCC, GPC3 has been suggested as a potential target for antibody-based therapy for liver cancer. A monoclonal antibody (GC33) is being evaluated in clinical studies as a single agent or in combination with Sorafenib to treat patients with advanced or metastatic HCC. Ongoing clinical trials will help define the utility of GPC3 as a novel target for liver cancer therapy.

PubMed Disclaimer

Figures

Figure 1
Figure 1
A working model of how soluble GPC3ΔGPI (sGPC3) proteins inhibit HCC cell growth. Soluble GPC3ΔGPI proteins may function as a dominant-negative form to inhibit the interactions between cell surface endogenous GPC3, Wnt, growth factors or ligands by sequestering these soluble factors away from the cell surface.
Figure 2
Figure 2
The glypican-Wnt/growth factor complex. A. The core protein of GPC3 facilitates or stabilizes the interaction between Wnt and Frizzled, thereby activating downstream signaling to stimulate HCC cell growth. B. The heparan sulfate (HS) chains of GPC3 may be used as storage sites for Wnt. SULF2-mediated desulfation of GPC3 releases stored Wnt and initiate binding to the Frizzled receptor, thus leading to Wnt signaling activation and HCC cell growth.
See this image and copyright information in PMC

References

    1. Pilia G, et al. Mutations in GPC3, a glypican gene, cause the Simpson-Golabi-Behmel overgrowth syndrome. Nat Genet. 1996;12(3):241–7. - PubMed
    1. Cano-Gauci DF, et al. Glypican-3-deficient mice exhibit developmental overgrowth and some of the abnormalities typical of Simpson-Golabi-Behmel syndrome. J Cell Biol. 1999;146(1):255–64. - PMC - PubMed
    1. Fransson LA. Glypicans. Int J Biochem Cell Biol. 2003;35(2):125–9. - PubMed
    1. Hsu HC, Cheng W, Lai PL. Cloning and expression of a developmentally regulated transcript MXR7 in hepatocellular carcinoma: biological significance and temporospatial distribution. Cancer Res. 1997;57(22):5179–84. - PubMed
    1. Nakatsura T, et al. Glypican-3, overexpressed specifically in human hepatocellular carcinoma, is a novel tumor marker. Biochem Biophys Res Commun. 2003;306(1):16–25. - PubMed

LinkOut - more resources